InnoCare Pharma Limited
9969
(1) 2024
(2) 2024
(3)
(4) 2024
(5) 2024
(6)
2024 12 17
8 8 EGM-1 EGM-2
(www.hkexnews.hk)
(www.innocarepharma.com)
48 2024 12 15
183 17M
2024 12 15
2024 11 28
................................................ 1
.................................................................... 2
............................................................. 8
1. ............................................................... 9
2. ............................................. 9
3. 2024 ................................ 10
4. 2024 ...... 51
5. .................................... 54
6. 2024 55
....................................................
7. 2024 ............. 57
8. ... 59
9. ...................................................... 62
10. ............................................. 62
11. .......................................................... 62
12. .................................................... 63
13. .......................................................... 64
14. .......................................................... 64
–i–
— 2024 .................................. I-1
— ...................................... II-1
....................................................... EGM-1
– ii –
(www.hkexnews.hk) (www.innocarepharma.com)
48 2024 12 15
183
17M 2024 12 15
183 17 1712–1716
(852) 2862 8555
(852) 2865 0990
www.computershare.com/hk/contact
(www.hkexnews.hk)
(www.sse.com.cn) (www.innocarepharma.com)
–1–
2023 2023 6 2 2023
2023 5
3
2023 2023 8 31
2023 8 16
2024 2024
14A.06(2)
2015 11 3
9969
688428
–2–
2024 12 17
9,870,200
80%
6.65
4 —
–3–
0.000002
2024
5%
2024
(i)
12
0.1% (ii)
(iii)
–4–
XIVA
2024 11 26
2,467,550
20%
0.000002
6. 2024
–5–
571
0.000002
622
15
–6–
%
–7–
InnoCare Pharma Limited
9969
Ogier Global (Cayman) Limited
89 Nexus Way, Camana Bay
Grand Cayman, KY1-9009
Cayman Islands
8 8
248
40
(1) 2024
(2) 2024
(3)
(4) 2024
(5) 2024
(6)
–8–
1.
EGM-1
EGM-2
(1)
2024 (2) 2024
(3) (4)
2024 (5)
2024
2.
(i) 2023 8 31 2023 8 31
2023 (ii) 2023 6 2
2023
(iii) 2023 4 28 2023
(i) 2023 8 16
2023 2023 (ii)
2023 5 3 2023
2023
2023 2023
3.43% 60,430,357 (i)2023 2023
(ii)2023 2023
–9–
2023
2.92% 51,481,607 0.51%
8,948,750 3.43%
1,764,321,452 1,762,567,202
3.43%
2023
(i) 7,209,000 (ii) 1,737,000
(iii) (a)2023 (b)
2,750 2023 12
12
3. 2024
2024 11 26 2024
2024
2024
I.2024 2024
2024 11 26 2024
2024
– 10 –
2024 2024
2024
2024
I. 2024
2023
2024
2024
12,337,750 0.70%
6. 2024
2024
20%
2024
10% 2024
– 11 –
1%
12
0.1%
II.
(I)
(II)
III.
1,233.775
176,256.7202 0.70%
987.020
176,256.7202 0.56%
80.00% 246.755
176,256.7202 0.14%
20.00%
– 12 –
IV.
(I)
1.
2.
5%
2024 2023
– 13 –
(II)
79 2023 12
31 1,089 7.25%
1.
2.
5%
12
– 14 –
12
(III)
0.1%
4.
2024 8.
— (i)
1.
258.00 20.91% 0.15%
70.00 5.67% 0.04%
– 15 –
60.00 4.86% 0.03%
10.00 0.81% 0.01%
398.00 32.26% 0.23%
2.
75 589.02 47.74% 0.33%
987.02 80.00% 0.56%
3. 246.755 20.00% 0.14%
1,233.775 100.00% 0.70%
1
1%
12
0.1%
– 16 –
20% 2023
2023
10%
2
5%
3
(IV)
1.
10
2. 5
V.
(I)
77
(II)
60
60
– 17 –
60
12 12
1.
30
(1)
(2)
60
2.
– 18 –
(III)
1.
2.
3.
4.
– 19 –
17 25%
29
29 25%
41
41 25%
53
53 25%
65
– 20 –
2025
12 25%
24
24 25%
36
36 25%
48
48 25%
60
– 21 –
2025
17 25%
29
29 25%
41
41 25%
53
53 25%
65
– 22 –
2024
(IV)
15 —
1.
25%
– 23 –
2.
6 6
15 —
VI.
(I)
6.65
6.65
(II)
– 24 –
1. 1
1 1
12.95 50.00% 6.47
2. 20
20 20
13.30 50.00% 6.65
3. 60
60 60
12.54 50.00% 6.27
4. 120
120 120
10.81 50.00% 5.40
(i) 2024
(ii)
2024
VII.
(I)
– 25 –
1.
(1)
(2)
(3) 36
(4)
(5)
2.
(1) 12
(2) 12
(3) 12
(4)
(5)
(6)
– 26 –
(II)
1.
(1)
(2)
(3) 36
(4)
(5)
2.
(1) 12
(2) 12
(3) 12
– 27 –
(4)
(5)
(6)
1
2
2024
2024
2024
3.
12
– 28 –
4.
2025–2028
A B C
100% 80% 70%
2025
1. 2025 1. 2025 1. 2025
20 17.5 15
2. 2025 8 2. 2025 7 2. 2025 6
I I I
II III II III II III
2026
1. 2025–2026 1. 2025–2026 1. 2025–2026
60 47.5 35
2. 2025–2026 2. 2025–2026 2. 2025–2026
16 14 12
I II III I II III I II III
– 29 –
A B C
100% 80% 70%
2027
1. 2025–2027 1. 2025–2027 1. 2025–2027
110 87.5 65
2. 2025–2027 2. 2025–2027 2. 2025–2027
24 21 18
I II III I II III I II III
2028
1. 2025–2028 1. 2025–2028 1. 2025–2028
170 137.5 105
2. 2025–2028 2. 2025–2028 2. 2025–2028
32 28 24
I II III I II III I II III
– 30 –
2025
2025–2028
2025
2026–2029
A B C
100% 80% 70%
2026
1. 2025–2026 1. 2025–2026 1. 2025–2026
60 47.5 35
2. 2025–2026 2. 2025–2026 2. 2025–2026
16 14 12
I II III I II III I II III
– 31 –
A B C
100% 80% 70%
2027
1. 2025–2027 1. 2025–2027 1. 2025–2027
110 87.5 65
2. 2025–2027 2. 2025–2027 2. 2025–2027
24 21 18
I II III I II III I II III
2028
1. 2025–2028 1. 2025–2028 1. 2025–2028
170 137.5 105
2. 2025–2028 2. 2025–2028 2. 2025–2028
32 28 24
I II III I II III I II III
– 32 –
A B C
100% 80% 70%
2029
1. 2025–2029 1. 2025–2029 1. 2025–2029
240 197.5 155
2. 2025–2029 2. 2025–2029 2. 2025–2029
40 35 30
I II III I II III I II III
5.
ME & ME Above ME- BE
ME & ME
Above ME- BE
100% 80% 0
– 33 –
=
(III)
– 34 –
2024
VIII.
(I)
1.
2.
3.
4. 6
5.
10
5
– 35 –
6.
7.
1/2
5%
12
0.1%
8.
(II)
1.
2.
– 36 –
3.
4. 60
60
3
12
12
(III)
1.
– 37 –
2.
(IV)
1.
2.
(1)
(2)
3.
(V)
1.
2.
– 38 –
3.
IX.
(I)
1.
Q Q0 (1 n)
Q0 n
Q
2.
Q Q0 P1 (1 n) (P1 P2 n)
Q0 P1
– 39 –
P2 n
Q
3.
Q Q0 n
Q0 n 1
n Q
4.
(II)
1.
P P0 (1 n)
P0 n
P
– 40 –
2.
P P0 (P1 P2 n) [P1 (1 n)]
P0 P1 P2
n P
3.
P P0 n
P0 n P
4.
P P0 – V
P0 V P
P 1
5.
(III)
– 41 –
X.
11 — 22 —
(I)
—
11 — 22 —
Black-Scholes
2024 11 26 987.02
1. 12.81 2024
11 26
2. 17 29 41 53
– 42 –
3. 35.2014% 33.7426% 34.8850% 35.5328%
17 29 41 53
4. 1.3603% 1.3852% 1.4451% 1.5554%
1 2 3 4
(II)
2024 12
2024 2025 2026 2027 2028 2029
987.02 6,657.45 111.57 2,677.56 1,984.11 1,148.13 586.08 150.01
1.
– 43 –
2.
XI.
(I)
1.
2.
3.
– 44 –
4.
5.
6.
7.
8.
– 45 –
(II)
1.
2.
3.
4.
5.
6.
7.
– 46 –
8.
9.
XII.
(I)
1.
(1)
(2)
(3) 36
(4)
(5)
2.
(1)
– 47 –
(2)
3.
(II)
1.
(1) 12
(2) 12
(3) 12
(4)
(5)
(6)
– 48 –
2.
3.
4.
– 49 –
5.
(1)
(2)
6.
(1)
(2)
– 50 –
7.
(III)
60
4. 2024
2024 2024
12 0.1%
– 51 –
3.
2024
2024
60
2,580,000
6.65
(i) 6.16
(ii) 12.81 13.86
2024
17
25%
– 52 –
2025
2024
2024
– 53 –
(i)
2024
(ii)
2024
8.
— (i)
5.
– 54 –
6. 2024
12,337,750
0.70%
4.13%
3. 2024
2024
82,046,037.50
12,337,750
2024
6.65
VI.
0.000002
24.6755
– 55 –
(1)
266,282,967 278,620,717
1,496,284,235 1,496,284,235
1,762,567,202 1,774,904,952
1.
(1)
75.83% 75.82%
1.
12 12
– 56 –
7. 2024
2024
2024
1.
2.
3.
4.
5.
6.
– 57 –
7.
8.
9.
10.
11.
12.
13.
– 58 –
8.
(i)
17.04(1) 2024
17.04(2) 17.04(4)
12
0.15% 0.1%
4
100,951,416 5.73%
– 59 –
(i)
12 1% (ii)
12
0.1%
(ii)
17.03(13)
17.03(13) 17.03(13)
2024 11
14 17.03(13)
(i)
2024
48
2024
(ii)
– 60 –
(iii)
12,337,750 1,762,567,202
0.70% (iv)
(iii)
2024 11 14
8.20 13.26(1) 2024
(a) 6.12
(i)
75% (ii)
6.12(1)
10%
(b) 6.15
(c) 13.36(2)(b)
– 61 –
10%
9.
(1) 2024
(2) (3)
2024 (4) 2024
2,580,000 (5)
2024 2024 12 17
8 8
EGM-1 EGM-2
(http://www.hkexnews.hk)
(www.innocarepharma.com)
10.
2024 12 12
2024 12 17
2024 12 11
183 17 1712–1716
11.
2024
EGM-1 EGM-2
– 62 –
12.
77
(i)
2024 2,580,000 4
(ii)
(1) 2024
(2) (3) 2024
(5) 2024
17.05A
8,318,000
– 63 –
13.
2024
14
2024
14.
2024 11 28
– 64 –
2024
A 688428 A
09969
2024
– I-1 –
2024
4 —
– I-2 –
2024
1,233.775
176,256.7202 0.70%
987.02
176,256.7202 0.56% 80.00%
246.755
176,256.7202 0.14% 20.00%
20%
10%
1%
12 0.1%
6.65
– I-3 –
2024
79 2023 12 31
1,089 7.25%
12
12
77
36
– I-4 –
2024
12
12
12
60
60
– I-5 –
2024
60
– I-6 –
2024
.................................................................... I-2
............................................................... I-2
........................................................... I-9
........................................ I-13
.......................................... I-14
..................................... I-15
...................... I-17
................ I-20
.................... I-26
................................... I-27
................................. I-39
.......................... I-43
........................................ I-45
............................... I-48
– I-7 –
2024
............................... I-50
......................................................... I-55
– I-8 –
2024
InnoCare Pharma Limited
2024
– I-9 –
2024
2024 11 26
2015 2016 9 6
2016 2016 9 6
2018 2018 11 28
2015 2016
2018
2023 2023 6 2 2023
2023 2023 8 31
– I-10 –
2024
2024 2024 3 28
(i)
12
0.1%
(ii) (iii)
4 —
(InnoCare Pharma Limited)
– I-11 –
2024
1
2
– I-12 –
2024
2023
2023 2024
2023 8 11 2023 8 31
(1) 2023
8,948,750
8,946,000 2,750
(2) 2023
51,481,607
(3) 2024
176,258,245
20%
10%
– I-13 –
2024
12
0.1%
– I-14 –
2024
Jisong Cui Renbin Zhao
5%
79 2023
12 31 1,089 7.25%
1
2
– I-15 –
2024
Jisong Cui Renbin Zhao
5% Jisong Cui
Renbin Zhao
Jisong Cui Renbin Zhao
12
12
10
5
– I-16 –
2024
1,233.775
176,256.7202 0.70% 987.02
176,256.7202 0.56%
80.00% 246.755
176,256.7202 0.14% 20.00%
– I-17 –
2024
Jisong Cui 0.1%
12 0.1%
Jisong Cui 258.00 20.91% 0.15%
Xiangyang Chen 70.00 5.67% 0.04%
Renbin Zhao 60.00 4.86% 0.03%
10.00 0.81% 0.01%
398.00 32.26% 0.23%
– I-18 –
2024
589.02 47.74% 0.33%
75
987.02 80.00% 0.56%
246.755 20.00% 0.14%
1,233.775 100.00% 0.70%
1
1%
12 0.1%
20%
10%
2 Jisong Cui Renbin Zhao
5%
3
– I-19 –
2024
77
60
60
60
12 12
30
1
2
– I-20 –
2024
60
– I-21 –
2024
17 25%
29
29 25%
41
41 25%
53
53 25%
65
– I-22 –
2024
2025
12 25%
24
24 25%
36
36 25%
48
48 25%
60
– I-23 –
2024
2025
17 25%
29
29 25%
41
41 25%
53
53 25%
65
– I-24 –
2024
15 —
25%
6
6
15 —
– I-25 –
2024
6.65
6.65
1 1
1 12.95 50.00%
6.47
20
20 20 13.30
50.00% 6.65
60
60 60 12.54
50.00% 6.27
– I-26 –
2024
120
120 120 10.81
50.00% 5.40
1
2
3 36
4
5
1 12
– I-27 –
2024
2 12
3 12
4
5
6
1
2
3 36
4
5
– I-28 –
2024
1 12
2 12
3 12
4
5
6
12
– I-29 –
2024
2025–2028
A B C
100% 80% 70%
2025
1 2025 1 2025 1 2025
20 17.5 15
2 2025 8 2 2025 7 2 2025 6
I-III I-III I-III
– I-30 –
2024
A B C
100% 80% 70%
2026
1 2025–2026 1 2025–2026 1 2025–2026
60 47.5 35
2 2025–2026 2 2025–2026 2 2025–2026
16 14 12
I-III I-III I-III
– I-31 –
2024
A B C
100% 80% 70%
2027
1 2025–2027 1 2025–2027 1 2025–2027
110 87.5 65
2 2025–2027 2 2025–2027 2 2025–2027
24 21 18
I-III I-III I-III
– I-32 –
2024
A B C
100% 80% 70%
2028
1 2025–2028 1 2025–2028 1 2025–2028
170 137.5 105
2 2025–2028 2 2025–2028 2 2025–2028
32 28 24
I-III I-III I-III
– I-33 –
2024
2025 2025–2028
2025 2026–2029
A B C
100% 80% 70%
2026
1 2025–2026 1 2025–2026 1 2025–2026
60 47.5 35
2 2025–2026 2 2025–2026 2 2025–2026
16 14 12
I-III I-III I-III
– I-34 –
2024
A B C
100% 80% 70%
2027
1 2025–2027 1 2025–2027 1 2025–2027
110 87.5 65
2 2025–2027 2 2025–2027 2 2025–2027
24 21 18
I-III I-III I-III
– I-35 –
2024
A B C
100% 80% 70%
2028
1 2025–2028 1 2025–2028 1 2025–2028
170 137.5 105
2 2025–2028 2 2025–2028 2 2025–2028
32 28 24
I-III I-III I-III
– I-36 –
2024
A B C
100% 80% 70%
2029
1 2025–2029 1 2025–2029 1 2025–2029
240 197.5 155
2 2025–2029 2 2025–2029 2 2025–2029
40 35 30
I-III I-III I-III
– I-37 –
2024
ME & ME Above
ME- BE
ME & ME
Above ME- BE
100% 80% 0
=
– I-38 –
2024
6
– I-39 –
2024
10 5
1/2
5%
12
0.1%
– I-40 –
2024
60
60
3
12
12
– I-41 –
2024
1
2
– I-42 –
2024
Q Q0 (1 n)
Q0 n
Q
Q Q0 P1 (1 n) (P1 P2 n)
Q0 P1
P2 n Q
– I-43 –
2024
Q Q0 n
Q0 n 1
n Q
P P0 (1 n)
P0 n
P
P P0 (P1 P2 n) [P1 (1 n)]
P0 P1 P2 n
P
– I-44 –
2024
P P0 n
P0 n P
P P0–V
P0 V P
P 1
11 — 22 —
– I-45 –
2024
—
11
— 22 —
Black-Scholes 2024 11 26
987.02
12.81 2024 11 26
17 29 41 53
35.2014% 33.7426% 34.8850% 35.5328%
17 29 41 53
1.3603% 1.3852% 1.4451% 1.5554% 1 2
3 4
– I-46 –
2024
2024 12
2024 2025 2026 2027 2028 2029
987.02 6,657.45 111.57 2,677.56 1,984.11 1,148.13 586.08 150.01
1
2
– I-47 –
2024
– I-48 –
2024
– I-49 –
2024
1
2
– I-50 –
2024
3 36
4
5
1
2
1 12
– I-51 –
2024
2 12
3 12
4
5
6
– I-52 –
2024
1
2
1
– I-53 –
2024
2
60
– I-54 –
2024
2024 11 26
– I-55 –
2024
2024
4 —
– II-1 –
– II-2 –
2025–2028
A B C
100% 80% 70%
2025
1 2025 1 2025 1 2025
20 17.5 15
2 2025 8 2 2025 7 2 2025 6
I-III I-III I-III
– II-3 –
A B C
100% 80% 70%
2026
1 2025–2026 1 2025–2026 1 2025–2026
60 47.5 35
2 2025–2026 2 2025–2026 2 2025–2026
16 14 12
I-III I-III I-III
– II-4 –
A B C
100% 80% 70%
2027
1 2025–2027 1 2025–2027 1 2025–2027
110 87.5 65
2 2025–2027 2 2025–2027 2 2025–2027
24 21 18
I-III I-III I-III
– II-5 –
A B C
100% 80% 70%
2028
1 2025–2028 1 2025–2028 1 2025–2028
170 137.5 105
2 2025–2028 2 2025–2028 2 2025–2028
32 28 24
I-III I-III I-III
2025 2025–2028
– II-6 –
2025 2026-2029
A B C
100% 80% 70%
2026
1 2025–2026 1 2025–2026 1 2025–2026
60 47.5 35
2 2025–2026 2 2025–2026 2 2025–2026
16 14 12
I-III I-III I-III
– II-7 –
A B C
100% 80% 70%
2027
1 2025–2027 1 2025–2027 1 2025–2027
110 87.5 65
2 2025–2027 2 2025–2027 2 2025–2027
24 21 18
I-III I-III I-III
– II-8 –
A B C
100% 80% 70%
2028
1 2025–2028 1 2025–2028 1 2025–2028
170 137.5 105
2 2025–2028 2 2025–2028 2 2025–2028
32 28 24
I-III I-III I-III
– II-9 –
A B C
100% 80% 70%
2029
1 2025–2029 1 2025–2029 1 2025–2029
240 197.5 155
2 2025–2029 2 2025–2029 2 2025–2029
40 35 30
I-III I-III I-III
ME & ME Above
ME- BE
– II-10 –
ME & ME
Above ME- BE
100% 80% 0
=
2025 2025–
2028
2025 2026-2029
15
– II-11 –
5
20
10
2024 11 26
– II-12 –
InnoCare Pharma Limited
9969
2024 12 17
8 8
1. 2024
2.
3. 2024
4. 2024 2,580,000
5. 2024
2024 11 28
– EGM-1 –
1. 2024 11 28
2.
3. 2024 12 12
2024 12 17
2024 12
11
183 17 1712–1716
4.
5.
6.
(48) 183
17M 2024 12 15
7.
8.
9.
www.innocarepharma.com www.hkexnews.hk
www.sse.com.cn
10.
– EGM-2 –